|
1
|
World Health Organization: GLOBOCAN 2022.
Graph production: IARC. Available from: http://gco.iarc.fr/today.
|
|
2
|
Feig C, Gopinathan A, Neesse A, Chan DS,
Cook N and Tuveson DA: The pancreas cancer microenvironment. Clin
Cancer Res. 18:4266–4276. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dauer P, Nomura A, Saluja A and Banerjee
S: Microenvironment in determining chemo-resistance in pancreatic
cancer: Neighborhood matters. Pancreatology. 17:7–12.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mews P, Phillips P, Fahmy R, Korsten M,
Pirola R, Wilson J and Apte M: Pancreatic stellate cells respond to
inflammatory cytokines: Potential role in chronic pancreatitis.
Gut. 50:535–541. 2002.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Veenstra VL, Damhofer H, Waasdorp C, van
Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG,
Busch OR, Chang DK, et al: ADAM12 is a circulating marker for
stromal activation in pancreatic cancer and predicts response to
chemotherapy. Oncogenesis. 7(87)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fröhlich C, Albrechtsen R, Dyrskjøt L,
Rudkjaer L, Ørntoft TF and Wewer UM: Molecular profiling of ADAM12
in human bladder cancer. Clin Cancer Res. 12:7359–7368.
2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kodama T, Ikeda E, Okada A, Ohtsuka T,
Shimoda M, Shiomi T, Yoshida K, Nakada M, Ohuchi E and Okada Y:
ADAM12 is selectively overexpressed in human glioblastomas and is
associated with glioblastoma cell proliferation and shedding of
heparin-binding epidermal growth factor. Am J Pathol.
165:1743–1753. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Le Pabic H, Bonnier D, Wewer UM, Coutand
A, Musso O, Baffet G, Clément B and Théret N: ADAM12 in human liver
cancers: TGF-beta-regulated expression in stellate cells is
associated with matrix remodeling. Hepatology. 37:1056–1066.
2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Peduto L, Reuter VE, Sehara-Fujisawa A,
Shaffer DR, Scher HI and Blobel CP: ADAM12 is highly expressed in
carcinoma-associated stroma and is required for mouse prostate
tumor progression. Oncogene. 25:5462–5466. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rocks N, Paulissen G, Quesada Calvo F,
Polette M, Gueders M, Munaut C, Foidart JM, Noel A, Birembaut P and
Cataldo D: Expression of a disintegrin and metalloprotease (ADAM
and ADAMTS) enzymes in human non-small-cell lung carcinomas
(NSCLC). Br J Cancer. 94:724–730. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Roy R, Wewer UM, Zurakowski D, Pories SE
and Moses MA: ADAM 12 cleaves extracellular matrix proteins and
correlates with cancer status and stage. J Biol Chem.
279:51323–51330. 2004.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yu J, Walter K, Omura N, Hong SM, Young A,
Li A, Vincent A and Goggins M: Unlike pancreatic cancer cells
pancreatic cancer associated fibroblasts display minimal gene
induction after 5-aza-2'-deoxycytidine. PLoS One.
7(e43456)2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dyczynska E, Sun D, Yi H, Sehara-Fujisawa
A, Blobel CP and Zolkiewska A: Proteolytic processing of delta-like
1 by ADAM proteases. J Biol Chem. 282:436–444. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Asakura M, Kitakaze M, Takashima S, Liao
Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro
H, et al: Cardiac hypertrophy is inhibited by antagonism of ADAM12
processing of HB-EGF: Metalloproteinase inhibitors as a new
therapy. Nat Med. 8:35–40. 2002.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang F, Sloss C, Zhang X, Lee SW and
Cusack JC: Membrane-bound heparin-binding epidermal growth factor
like growth factor regulates E-cadherin expression in pancreatic
carcinoma cells. Cancer Res. 67:8486–8493. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rahman FB, Kadowaki Y, Ishihara S, Tobita
H, Imaoka H, Fukuhara H, Aziz MM, Furuta K, Amano Y and Kinoshita
Y: Fibroblast-derived HB-EGF promotes Cdx2 expression in esophageal
squamous cells. Lab Invest. 90:1033–1048. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Korc M: Role of growth factors in
pancreatic cancer. Surg Oncol Clin N Am. 7:25–41. 1998.PubMed/NCBI
|
|
19
|
Dharmaraj N, Engel BJ and Carson DD:
Activated EGFR stimulates MUC1 expression in human uterine and
pancreatic cancer cell lines. J Cell Biochem. 114:2314–2322.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kopantzev EP, Kopantseva MR, Grankina EV,
Mikaelyan A, Egorov VI and Sverdlov ED: Activation of IGF/IGF-IR
signaling pathway fails to induce epithelial-mesenchymal transition
in pancreatic cancer cells. Pancreatology. 19:390–396.
2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yin T, Wang CY, Liu T, Zhao G and Zha YH:
Expression of Snail and E-cadherin in pancreatic carcinoma and
clinical significance thereof. Zhonghua Yi Xue Za Zhi.
86:2821–2825. 2006.PubMed/NCBI(In Chinese).
|
|
22
|
Gordon KJ, Dong M, Chislock EM, Fields TA
and Blobe GC: Loss of type III transforming growth factor beta
receptor expression increases motility and invasiveness associated
with epithelial to mesenchymal transition during pancreatic cancer
progression. Carcinogenesis. 29:252–262. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang J, Zhang Z, Li R, Mao F, Sun W, Chen
J, Zhang H, Bartsch JW, Shu K and Lei T: ADAM12 induces EMT and
promotes cell migration, invasion and proliferation in pituitary
adenomas via EGFR/ERK signaling pathway. Biomed Pharmacother.
97:1066–1077. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Huang X and Xie X, Liu P, Yang L, Chen B,
Song C, Tang H and Xie X: Adam12 and lnc015192 act as ceRNAs in
breast cancer by regulating miR-34a. Oncogene. 37:6316–6326.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hariharan D, Saied A and Kocher HM:
Analysis of mortality rates for pancreatic cancer across the world.
HPB (Oxford). 10:58–62. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lambrecht BN, Vanderkerken M and Hammad H:
The emerging role of ADAM metalloproteinases in immunity. Nat Rev
Immunol. 18:745–758. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kveiborg M, Albrechtsen R, Couchman JR and
Wewer UM: Cellular roles of ADAM12 in health and disease. Int J
Biochem Cell Biol. 40:1685–1702. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nakayama Y and Yoshioka J: ADAM12 controls
a hypertrophic response in the heart through the distinct
descending pathways. Am J Physiol Heart Circ Physiol.
318:H209–H211. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang R, Godet I, Yang Y, Salman S, Lu H,
Lyu Y, Zuo Q, Wang Y, Zhu Y, Chen C, et al: Hypoxia-inducible
factor-dependent ADAM12 expression mediates breast cancer invasion
and metastasis. Proc Natl Acad Sci USA.
118(e2020490118)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Xu J, Wang Y, Jiang J, Yin C and Shi B:
ADAM12 promotes clear cell renal cell carcinoma progression and
triggers EMT via EGFR/ERK signaling pathway. J Transl Med.
21(56)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Özdemir BC, Pentcheva-Hoang T, Carstens
JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C,
Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts
and fibrosis induces immunosuppression and accelerates pancreas
cancer with reduced survival. Cancer Cell. 25:719–734.
2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Erkan M, Michalski CW, Rieder S,
Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H
and Kleeff J: The activated stroma index is a novel and independent
prognostic marker in pancreatic ductal adenocarcinoma. Clin
Gastroenterol Hepatol. 6:1155–1161. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu
Y, Yao Y and Li D: The epithelial to mesenchymal transition (EMT)
and cancer stem cells: Implication for treatment resistance in
pancreatic cancer. Mol Cancer. 16(52)2017.PubMed/NCBI View Article : Google Scholar
|
